Epcoritamab + Cyclophosphamide + Rituximab + Doxorubicin + Vincristine + Prednisone + Lenalidomide
Phase 1/2Active 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-Cell Non-Hodgkin Lymphoma
Conditions
B-Cell Non-Hodgkin Lymphoma
Trial Timeline
Mar 10, 2022 → Apr 1, 2025
NCT ID
NCT05201248About Epcoritamab + Cyclophosphamide + Rituximab + Doxorubicin + Vincristine + Prednisone + Lenalidomide
Epcoritamab + Cyclophosphamide + Rituximab + Doxorubicin + Vincristine + Prednisone + Lenalidomide is a phase 1/2 stage product being developed by AbbVie for B-Cell Non-Hodgkin Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT05201248. Target conditions include B-Cell Non-Hodgkin Lymphoma.
What happened to similar drugs?
3 of 20 similar drugs in B-Cell Non-Hodgkin Lymphoma were approved
Approved (3) Terminated (2) Active (15)
Hype Score Breakdown
Clinical
9
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05201248 | Phase 1/2 | Active |
Competing Products
20 competing products in B-Cell Non-Hodgkin Lymphoma